Prevalence of malignant hyperthermia and relationship with anesthetics in japan: Data from the diagnosis procedure combination database

Anesthesiology

Volumn 114, Issue 1, 2011, Pages 84-90

  Sumitani, Masahiko ^a   Uchida, Kanji ^a   Yasunaga, Hideo ^b   Horiguchi, Hiromasa ^b   Kusakabe, Yoshiomi ^a   Matsuda, Shinya ^c   Yamada, Yoshitsugu ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; ENFLURANE; HALOTHANE; ISOFLURANE; PANCURONIUM; PROPOFOL; ROCURONIUM; SEVOFLURANE; SUXAMETHONIUM; VECURONIUM;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; FEMALE; GENERAL ANESTHESIA; HUMAN; INFANT; JAPAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT HYPERTHERMIA; MORBIDITY; MORTALITY; NEWBORN; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SCHOOL CHILD; SEX DIFFERENCE;

EID: 78650704042     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e318200197d     Document Type: Article

References (33)

1. Denborough M: Malignant hyperthermia. Lancet 1998; 352: 1131-6
2. Monnier N, Kozak-Ribbens G, Krivosic-Horber R, Nivoche Y, Qi D, Kraev N, Loke J, Sharma P, Tegazzin V, Figarella-Branger D, Roméro N, Mezin P, Bendahan D, Payen JF, Depret T, Maclennan DH, Lunardi J: Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility. Hum Mutat 2005; 26:413-25
3. Monnier N, Krivosic-Horber R, Payen JF, Kozak-Ribbens G, Nivoche Y, Adnet P, Reyford H, Lunardi J: Presence of two different genetic traits in malignant hyperthermia families. Implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility. ANESTHESIOLOGY 2002; 97:1067-74
4. Ording H: Incidence of malignant hyperthermia in Denmark. Anesth Analg 1985; 64:700-4
5. Urwyler A, Hartung E: [Malignant hyperthermia]. Anaesthe-sist 1994; 43:557-69
6. Suyama H, Kawamoto M, Yuge O: Prevention and treatment of malignant hyperthermia in certified training hospitals in Japan: A questionnaire. J Anesth 2002; 16:207-10
7. Brady JE, Sun LS, Rosenberg H, Li G: Prevalence of malignant hyperthermia due to anesthesia in New York State, 2001-2005. Anesth Analg 2009; 109:1162-6
8. Gronert GA, Pessah IN, Muldoon SM, Tautz TJ: Malignant hyperthermia, Miller's Anesthesia, 6th edition. Edited by Miller RD. Philadelphia, Elsevier Churchill Livingstone, 2005, pp 1169-90
9. 2 + release from the sarcoplasmic reticulum of skeletal muscle. ANESTHESIOLOGY 1999; 91:179-86
10. Shulman M, Braverman B, Ivankovich AD, Gronert G: Sevoflurane triggers malignant hyperthermia in swine. ANESTHESIOLOGY 1981; 54:259-60
11. Migita T, Mukaida K, Hamada H, Kobayashi M, Nishino I, Yuge O, Kawamoto M: Effects of propofol on calcium homeostasis in human skeletal muscle. Anaesth Intensive Care 2009; 37:415-25
12. Pollock AN, McKenzie AJ, Hodges M, Snoeck MM: Propofol and malignant hyperthermia susceptibility. Anaesth Intensive Care 1997; 25:583-5
13. Plotz FB, Waalkens HJ, Verkade HJ, Strengers JL, Knoester H, Mandema JM: Fatal side-effects of continuous propofol infusion in children may be related to malignant hyperthermia. Anaesth Intensive Care 1996; 24:724
14. Matsuda S, Ishikawa KB, Kuwabara K, Fujimori K, Fushimi K, Hashimoto H: Development and use of the Japanese case-mix system. Eurohealth 2008; 14:25-30
15. Yasunaga H, Yanaihara H, Fuji K, Horiguchi H, Hashimoto H, Matsuda S: Impact of hospital volume on postoperative complications and in-hospital mortality after renal surgery: Data from the Japanese Diagnosis Procedure Combination Database. Urology 2010; 76:548-52
16. Kadono Y, Yasunaga H, Horiguchi H, Hashimoto H, Matsuda S, Tanaka S, Nakamura K: Statistics for orthopedic surgery 2006-2007: Data from the Japanese Diagnosis Procedure Combination database. J Orthop Sci 2010; 15:162-70
17. Kuwabara K, Matsuda S, Imanaka Y, Fushimi K, Hashimoto H, Ishikawa KB, Horiguchi H, Hayashida K, Fujimori K, Ikeda S, Yasunaga H: Injury severity score, resource use, and outcome for trauma patients within a Japanese administrative database. J Trauma 2010; 68:463-70
18. Park B, Messina L, Dargon P, Huang W, Ciocca R, Anderson FA: Recent trends in clinical outcomes and resource utilization for pulmonary embolism in the United States: Findings from the nationwide inpatient sample. Chest 2009; 136: 983-90
19. Larach MG, Localio AR Allen GC, Denborough MA, Ellis FR, Gronert GA, Kaplan RF, Muldoon SM, Nelson TE, Ording H, Rosenberg H, Waud BE, Wedel DJ: A clinical grading scale to predict malignant hyperthermia susceptibility. ANESTHESIOLOGY 1994; 80:771-9
20. Girard T, Urwyler A, Censier K, Mueller CR Zorzato F, Treves S: Genotype-phenotype comparison of the Swiss malignant hyperthermia population. Hum Mutat 2001; 18:357-8
21. Ichihara Y, Sasaki J, Kikuchi H, Ozawa M, Goto Y, Nonaka I: [Preliminary report: First identification of known mutation in the ryanodine receptor gene in a Japanese malignant hyperthermia pedigree.] Masui 2000; 49:404-6
22. Ibarra M CA, Wu S, Murayama K, Minami N, Ichihara Y, Kikuchi H, Noguchi S, Hayashi YK, Ochiai R, Nishino I: Malignant hyperthermia in Japan: Mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing. ANESTHESIOLOGY 2006; 104:1146-54
23. Migita T, Mukaida K, Kawamoto M, Kobayashi M, Yuge O: Fulminant-type malignant hyperthermia in Japan: Cumulative analysis of 383 cases. J Anesth 2007; 21:285-8
24. Larach MG, Gronert GA, Allen GC, Brandom BW, Lehman EB: Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg 2010; 110:498-507
25. Larach MG, Brandom BW, Allen GC, Gronert GA, Lehman EB: Cardiac arrests and deaths associated with malignant hyper-thermia in north america from 1987 to 2006: A report from the north american malignant hyperthermia registry of the malignant hyperthermia association of the United States. ANESTHESIOLOGY 2008; 108:603-11
26. Jenkins JG: Masseter muscle rigidity after vecuronium. Eur J Anaesthesiol 1999; 16:137-9
27. Albrecht A, Wedel DJ, Gronert GA: Masseter muscle rigidity and nondepolarizing neuromuscular blocking agents. Mayo Clin Proc 1997; 72:329-32
28. Hopkins PM: Malignant hyperthermia: Advances in clinical management and diagnosis. Br J Anaesth 2000; 85:118-28
29. Mukaida K, Maehara Y, Osawa K, Yuge O: [The relationship between muscle rigidity and CICR speed.] Masui-to-Sosei 1997; 33:S77-82
30. Rosenberg H, Fletcher JE: Masseter muscle rigidity and malignant hyperthermia susceptibility. Anesth Analg 1986; 65: 161-4
31. Littleford JA, Patel LR, Bose D, Cameron CB, McKillop C: Masseter muscle spasm in children: Implications of continuing the triggering anesthetic. Anesth Analg 1991; 72:151-60
32. Carroll JB: Increased incidence of masseter spasm in children with strabismus anesthetized with halothane and succinyl-choline. ANESTHESIOLOGY 1987; 67:559-61
33. Baker K, Raines DE: Intraanesthetic problems, Clinical Anesthesia Procedures of the Massachusetts General Hospital, 5th edition. Edited by Hurford WE, Balilin MT, Davison JK, Haspel KL, Rosow C. Philadelphia, Lippincott Williams & Wilkins, 1998, pp 287-312